Shelton Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Shelton Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-791	Closed	-$8.34K	–	746
2023 Q1	$8.34K	Hold	791	–	–	﹤0.01%	728
2022 Q4	$26.8K	Hold	791	–	–	﹤0.01%	679
2022 Q3	$38K	Hold	791	–	–	﹤0.01%	683
2022 Q2	$45K	Hold	791	–	–	﹤0.01%	711
2022 Q1	$64K	Buy	791 +108	+16%	+$16K	﹤0.01%	806
2021 Q4	$138K	Hold	683	–	–	﹤0.01%	823
2021 Q3	$184K	Hold	683	–	–	0.01%	783
2021 Q2	$176K	Hold	683	–	–	0.01%	809
2021 Q1	$205K	Hold	683	–	–	0.01%	765
2020 Q4	$174K	Hold	683	–	–	0.01%	700
2020 Q3	$170K	Hold	683	–	–	0.01%	711
2020 Q2	$237K	Sell	683 -32	-4%	-$9.98K	0.01%	527
2020 Q1	$192K	Sell	715 -57	-7%	-$17.6K	0.01%	551
2019 Q4	$250K	Buy	+772	New	+$224K	0.01%	628
2018 Q1	–	Sell	-930	Closed	-$833K	–	875
2017 Q4	$833K	Hold	930	–	–	0.05%	263
2017 Q3	$335K	Sell	930 -89	-9%	-$27.8K	0.02%	513
2017 Q2	$299K	Buy	1,019 +113	+12%	+$32.7K	0.02%	574
2017 Q1	$319K	Buy	906 +160	+21%	+$36K	0.02%	545
2016 Q4	$137K	Hold	746	–	–	0.01%	851
2016 Q3	$192K	Hold	746	–	–	0.02%	753
2016 Q2	$159K	Hold	746	–	–	0.01%	738
2016 Q1	$154K	Buy	746 +69	+10%	+$13.3K	0.01%	738
2015 Q4	$171K	Hold	677	–	–	0.02%	719
2015 Q3	$111K	Buy	+677	New	+$120K	0.01%	731

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Shelton Capital Management's NKTR Position: Q2 2023 in Review

Shelton Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 791 shares — an estimated $8.34K sold.

Shelton Capital Management first reported a position in NKTR in Q3 2015 and held it in 24 quarters. The position peaked at $833K in Q4 2017. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Shelton Capital Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Shelton Capital Management sold 791 Nektar Therapeutics shares in Q2 2023, an estimated $8.34K.
Shelton Capital Management first reported a position in Nektar Therapeutics in Q3 2015 and held it in 24 quarters.
Shelton Capital Management's Nektar Therapeutics position peaked at $833K in Q4 2017.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Shelton Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.